Bavarian Nordic A/S’s respiratory syncytial virus vaccine program has been markedly de-risked after the administration of candidate MVA-BN RSV in a Phase II adult challenge trial led to a big reduction in viral load compared with placebo, paving the way for talks with regulators for the design of a Phase III study and with prospective partners to commercialize the product.
The Phase II trial enrolled 61 healthy adult volunteers aged 18 to 50 randomized to receive either a single vaccination...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?